Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Larimar Therapeutics Inc is a biotechnology business based in the US. Larimar Therapeutics shares (LRMR) are listed on the NASDAQ and all prices are listed in US Dollars. Larimar Therapeutics employs 28 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$12.79|
|52-week range||$7.80 - $25.87|
|50-day moving average||$12.51|
|200-day moving average||$11.65|
|Wall St. target price||$24.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.07|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||5.53%|
|1 month (2021-09-23)||6.85%|
|3 months (2021-07-23)||28.03%|
|6 months (2021-04-23)||-10.87%|
|1 year (2020-10-23)||-31.53%|
|2 years (2019-10-23)||1,644.17%|
|3 years (2018-10-23)||25.64%|
|5 years (2016-10-21)||267.53%|
|Gross profit TTM||$0|
|Return on assets TTM||-29.91%|
|Return on equity TTM||-54.62%|
|Market capitalisation||$214.7 million|
TTM: trailing 12 months
There are currently 497,827 Larimar Therapeutics shares held short by investors – that's known as Larimar Therapeutics's "short interest". This figure is 10.6% up from 450,143 last month.
There are a few different ways that this level of interest in shorting Larimar Therapeutics shares can be evaluated.
Larimar Therapeutics's "short interest ratio" (SIR) is the quantity of Larimar Therapeutics shares currently shorted divided by the average quantity of Larimar Therapeutics shares traded daily (recently around 63256.289707751). Larimar Therapeutics's SIR currently stands at 7.87. In other words for every 100,000 Larimar Therapeutics shares traded daily on the market, roughly 7870 shares are currently held short.
However Larimar Therapeutics's short interest can also be evaluated against the total number of Larimar Therapeutics shares, or, against the total number of tradable Larimar Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Larimar Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Larimar Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0577% of the tradable shares (for every 100,000 tradable Larimar Therapeutics shares, roughly 58 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Larimar Therapeutics.
Find out more about how you can short Larimar Therapeutics stock.
We're not expecting Larimar Therapeutics to pay a dividend over the next 12 months.
Larimar Therapeutics's shares were split on a 1:12 basis on 28 May 2020. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Larimar Therapeutics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Larimar Therapeutics shares which in turn could have impacted Larimar Therapeutics's share price.
Larimar Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.